Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris - A pilot study

European Journal of Dermatology

Volumn 18, Issue 4, 2008, Pages 433-439

  Marcinkiewicz, Janusz ^a   Wojas Pelc, Anna ^a   Walczewska, Maria ^a   Lipko Godlewska, Sylwia ^a   Jachowicz, Renata ^a   Maciejewska, Aldona ^a   Białecka, Anna ^b   Kasprowicz, Andrzej ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Center of Microbiological Research and Autovaccines Ltd   (Poland)

Author keywords

Acne vulgaris; Clindamycin; Propionibacterium acnes; Taurine bromamine (N bromotaurine); Topical treatment

Indexed keywords

CLINDAMYCIN; TAURINE BROMAMINE; TAURINE DERIVATIVE;

ACNE VULGARIS; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BLISTER; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ECZEMA; FEMALE; HEAT; HUMAN; MALE; PAPULE; PARALLEL DESIGN; PILOT STUDY; PROPIONIBACTERIUM ACNES; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ABRASION; SKIN INFLAMMATION; SKIN REDNESS; SKIN SWELLING; SKIN TINGLING; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT DURATION; TREATMENT RESPONSE;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADULT; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; EMOLLIENTS; FACE; FEMALE; GELS; HUMANS; MALE; PILOT PROJECTS; TAURINE;

EID: 47749134481     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0460     Document Type: Article

References (40)

1. Burkhart CG, Burkhart CN, Lehmann PF Acne: a review of immunologic and microbiologic factors. Postgrad Med J 1999; 75: 328-31.
2. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-7.
3. Koreck A, Pivarcsi A, Dobozy A, Kemeny L. The role of innate immunity in the pathogenesis of acne. Dermatology 2003; 206: 96-105.
4. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. Am J Clin Dermatol 2001; 2: 263-6.
5. Jappe U, Ingham E, Henwood J, Holland KT. Propionibacterium acnes and inflammation in acne; P. acnes has T-cell mitogenic activity. Br J Dermatol 2002; 146(2): 202-9.
6. Nishijima S, Kurokawa I, Katoh N, Watanabe K. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J Dermatol 2000; 27(5): 318-23.
7. Guay DR. Topical clindamycin in the management of acne vulgaris. Expert Opin Pharmacother 2007; 8(15): 2625-64.
8. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196(1): 130-4.
9. Tan HH. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am J Clin Dermatol 2004; 5(2): 79-84.
10. Warner GT, Plosker GL. Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. Am J Clin Dermatol 2002; 3: 349-60.
11. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004; 64: 2389-97.
12. Leyden JJ. Antibiotic resistance in the topical treatment of acne vulgaris. Cutis 2004; 73: 6-10.
13. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206(1): 54-6.
14. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Peréz Del Pulgar JI, Rollman O, Török L, Eady EA, Cove JH. Antibiotic - resistant acne: lessons from Europe. Br J Dermatol 2003; 148(3): 467-78.
15. Taylor GA, Shalita AR. Benzoyl peroxide-based combination therapies for acne vulgaris: a comparative review. Am J Clin Dermatol 2004; 5(4): 261-5.
16. Thomas EL, Bozeman PM, Jefferson MM, King CC. Oxidation of bromide by the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase. J Biol Chem 1995; 270: 2906-13.
17. Henderson JP, Byun J, Williams MV, Mueller DM, McCormick ML, Heinecke JW. Production of brominating intermediates by myeloperoxidase. J Biol Chem 2001; 11: 7867-75.
18. Nagl M, Hess MW, Pfaller K, Hengster P, Gottardi W. Bactericidal activity of micromolar N-chlorotaurine: evidence for its antimicrobial function in the human defense system. Antimicrob Agents Chemother 2000; 44: 2507-13.
19. Park E, Schuller-Levis G, Jia JH, Quinn MR. Preactivation exposure of RAW 264.7 cells to taurine chloramine attenuates subsequent production of nitric oxide and expression of iNOS mRNA. J Leukoc Biol 1997; 61: 161-6.
20. Marcinkiewicz J, Grabowska A, Bereta J, Bryniarski K, Nowak B. Taurine chloramine down-regulates the generation of murine neutrophil inflammatory mediators. Immunopharmacology 1998; 40: 27-38.
21. Marcinkiewicz J, Mak M, Bobek M, Biedroń R, Białecka A, Koprowski M, Kontny E, Maśliński W. Is there a role of taurine bromamine in inflammation? Interactive effects with nitrate and hydrogen peroxide. Inflamm Res 2005; 54: 42-9.
22. Olszanecki R, Marcinkiewicz J. Taurine chloramines and Taurine bromamine induce heme-oxygenase-1 in resting and LPS-stimulated J774.2 macrophages. Amino Acids 2004; 27: 29-35.
23. Marcinkiewicz J, Chain B, Nowak B, Grabowska A, Bryniarski K, Baran J. Antimicrobial and cytotoxic activity of hypochlorous acid: interactions with taurine and nitrite. Inflamm Res 2000; 49: 280-9.
24. Marcinkiewicz J, Biedron R, Biafecka A, Kasprowicz A, Mak M, Targosz M. Susceptibility of Propionibacterium acnes and Staphylococcus epidermidis to killing by MPO-halide system products. Implication for taurine bromamine as a new candidate for topical therapy in treating acne vulgaris. Arch Immunol Ther Exp (Warsz) 2006; 54(1): 61-8.
25. Nagl M, Nguyen VA, Gottardi W, Ulmer H, Hopfl R. Tolerability and efficacy of N-chlorotaurine in comparison with chloramines T for the treatment of chronic leg ulcers with a purulent coating: a randomized phase II study. Br J Dermatol 2003; 149: 590-7.
26. Thomas EL, Grisham MB, Jefferson MM. Preparation and characterization of chloramines. Methods Enzymol 1986; 132: 569-71.
27. O'Brien SC, Lewis JB, Cunliffe WJ. The Leeds Revised Acne Grading System. J Dermatol Traet 1989; 9: 215-20.
28. Tscnen E. Potential role for a new combination topical therapy in treating mild to moderate acne vulgaris. Cutis 2001; 67(Suppl 2): 25-7.
29. Dreno B, Bettoli V, Ochsendorf F, Perez-Lopez M, Mobacken H, Degreef H, Layton A. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol 2006; 16(5): 565-71.
30. Leyden JJ. Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes. Cutis 2002; 69(6): 475-80.
31. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54(1): 73-81.
32. Alirezaï M, Gerlach B, Horvath A, Forsea D, Briantais P, Guyomar M. Results of a randomised, multicentre study comparing a new water-based gel of clindamycin 1% versus clindamycin 1% topical solution in the treatment of acne vulgaris. Eur J Dermatol 2005; 15(4): 274-8.
33. Del Rosso JQ. Study results of benzoyl peroxide 5%/ clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol 2007; 6(6): 616-22.
34. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196(1): 119-25.
35. Langner A, Sheehan-Dare R, Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 2007; 21(3): 311-9.
36. Gans EH, Kligman AM. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J Dermatolog Treat 2002; 13(3): 107-10.
37. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121(1): 51-7.
38. Akamatsu H, Horio T. The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. Dermatology 1998; 196: 82-5.
39. Akamatsu H, Horio T, Hattori K. Increased hydrogen peroxide generation by neutrophils from patients with acne inflammation. Int J Dermatol 2003; 42: 366-9.
40. Biafecka A, Mak M, Biedroń R, Bobek M, Kasprowicz A, Marcinkiewicz J. Different pro-inflammatory and immunogenic potentials of Propionibacterium acnes and Staphylococcus epidermidis: implication for chronic inflammatory acne. Arch Immunol Ther Exp (Warsz) 2005; 53: 79-85.